ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. There are plenty of strategies for discovering value stocks, but we have ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along ...

Review the current ACADIA Pharmaceuticals Inc (ACAD:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if ACAD is the best investment for you.

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 26.1% in that time frame, outperforming the S&P 500.

Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been. The biotech won approval last year for its lead product, Nuplazid, in treating Parkinson's disease psychosis.

We have a conviction buy rating on Acadia Pharmaceuticals' common stock (price target of $47.57 based on sum-of-the parts DCF method). The company is also an attractive acquisition target.

Acadia Pharmaceuticals (ACAD 14.48%) is having a strong session Tuesday. Specifically, the drugmaker's shares were up by a healthy 6.7% on moderate volume at 10:02 a.m. ET.